Spherix’s recent study of 507 IgA nephropathy (IgAN) patients reveals a disconnect between treatment goals and real-world disease management, with most patients exhibiting high proteinuria levels despite being perceived as healthy by their nephrologists. Standard treatments like ACE inhibitors, ARBs, and SGLT2 inhibitors remain foundational, but branded therapies like Tarpeyo and Filspari are gaining traction as second- and third-line options, reflecting a shift towards targeted approaches. While nephrologists are interested in combination therapy, payer dynamics influence these decisions.
This data underscores the evolving landscape of IgAN treatment. The persistent presence of high proteinuria despite standard care emphasizes the need for more effective therapies and highlights an opportunity for emerging treatments to address this unmet need. The increasing adoption of branded therapies indicates a willingness among nephrologists to embrace novel, targeted approaches, which could lead to improved patient outcomes. This shift presents both a challenge and an opportunity for pharmaceutical companies developing new IgAN treatments.
The study highlights the growing use of SGLT2 inhibitors, often alongside ACEi/ARBs, and the increasing adoption of Tarpeyo and Filspari as second- and third-line therapies. Fabhalta, a recent market entrant, has seen slower uptake. Nephrologists are anticipating the potential arrival of new treatments like Novartis’ atrasentan and dual APRIL/BAFF inhibitors, which could reshape the treatment paradigm.
The IgAN treatment landscape is poised for significant change. The anticipated arrival of new therapies, coupled with the increasing adoption of existing branded treatments, points toward a more targeted and potentially more effective approach to managing IgAN. This evolving landscape presents an opportunity for improved patient outcomes and underscores the importance of ongoing research and development in this area.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
